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Abstract 
There is evidence that a key feature in Borderline Personality Disorder (BPD) is the difficulty to 
reflect on one’s own as well as on other people’s state of mind. So far, no study has examined 
the link between metacognition and symptom change presented by BPD patients across 
treatment. This preliminary pilot study represents a first step in describing impairments in 
different dimensions of metacognition and their connection with the symptoms presented by a N 
= 10 BPD sample. The transcripts from the first and the penultimate session of a ten-session 
version of Good Psychiatric Management were analysed. The global score and the three 
subscales of the Metacognition Assessment Scale-Revised (MAS-R) were used in order to assess 
metacognitive abilities: Understanding of one’s own Mind, Understanding of Other’s Mind, and 
Mastery. Symptoms were assessed with the OQ-45. Results show a general low level of 
metacognition. Therapy sessions with BPD patients seem to be characterized by impairments in 
metacognition, notably in the reflection on other’s states of mind and in the use of this 
information to solve conflicts and problems. Moreover, sessions highlighting a higher level of 
the Understanding of Other’s Mind at the onset of treatment were linked with better outcome 
compared to sessions showing poorer metacognitive abilities in this area. Implications for an 
integrated treatment for BPD and future research are discussed. 
Key-Words: metacognition, borderline personality disorder, psychotherapy, outcome 
 
 
 
 
 
METACOGNITION AND SYMPTOM CHANGE IN BPD 
 4 
  
The understanding and treatment of BPD requires investigating core mechanisms of 
pathology, which can then be the target of intervention across different psychotherapeutic 
perspectives. The past decades saw the emergence of many studies focusing on the impairments 
of BPD patients to reflect upon their states of mind and those of others (Bateman & Fonagy, 
2004; Fischer-Kern, Buchheim, Hörz et al., 2010; Fischer-Kern, Doering, Taubner et al., 2015; 
Fonagy, 1991; Gullestad, Johansen, Høglend et al., 2013; Katznelson, 2014; Kernberg, Diamond, 
Yeomans et al., 2008; Levy et al., 2006; Semerari, Carcione, Dimaggio et al., 2005). This set of 
abilities has been defined with different, often overlapping terms (Choi-Kain & Gunderson, 
2008; Dimaggio & Brüne, 2016) such as “social cognition” (Fiske & Haslam, 1996), “theory of 
mind” (Brüne, 2005), “mentalization” (Bateman & Fonagy, 2004) or “metacognition” (Semerari 
et al., 2003). Throughout this study, the term metacognition will be used as it is consistent with 
the tradition underlying the instrument used here to analyse this ability. Difficulties in 
understanding mental states range from poor awareness of one’s own feelings, difficulties in 
inferring the thoughts and feelings underlying others’ behaviours, and the inability to connect 
different mental states in an integrated narrative. Indeed, poor skills in emotional recognition and 
reflection can be at the root of many aspects of BPD pathology, such as emotional dysregulation, 
impulsivity, self-harm and suicidality (Bateman & Fonagy, 2004). Social conflicts, poor sense of 
identity and poor quality of relationships can also stem from difficulties in understanding both 
one’s own and others’ mental states and using this knowledge to foster prosocial communication. 
Difficulties in understanding mental states are believed to be both a treatment target and a 
possible predictor of change in psychotherapy, and therefore need to be included in an integrated 
treatment for personality disorders (Livesley, Dimaggio, & Clarkin, 2016). On the one hand, 
good outcome therapies are supposed to foster patients’ skills to understand mental states and to 
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use this information to cope with stressors, and thus to live a more adapted life (Bateman & 
Fonagy, 2010). On the other hand, people with metacognitive difficulties can have more 
problems in understanding the therapeutic process and fruitfully using the contents of the therapy 
exchange (Gullestad et al., 2013). It is therefore to be expected that good metacognition at 
treatment onset predicts better outcome, and also that good outcome treatments yield changes in 
the ability to understand mental states. 
In this paper we first describe the definition of metacognition and the different mentalistic 
impairments present in BPD. We then review evidence for the possible role of metacognition in 
the psychotherapeutic process of BPD. We finally frame research questions about metacognition 
in a short-term treatment for BPD. 
Metacognition: Definitions and assessment 
Metacognition includes a range of capacities human beings use to identify mental states, 
both in oneself and others, reason about them, forming complex and integrated representations of 
oneself and others, and use mentalistic knowledge for problem solving (Carcione, Dimaggio, 
Conti et al., 2010; Semerari, Carcione, Dimaggio et al., 2007). A certain overlap exists between 
metacognition and mentalization, defined by Bateman and Fonagy (2004, p.21) as “the mental 
process by which an individual implicitly and explicitly interprets the actions of himself or 
herself and others as meaningful on the basis of intentional mental states such as personal 
desires, needs, feelings, beliefs, and reasons”. Mentalization has been operationalized with the 
Reflective Function Scale (RFS; Fonagy, Target, Steele & Steele, 1998) which aims to assess the 
quality of mentalization and involves different dimensions, as those concerning the self and 
others, implicit and explicit modes of functioning and cognitive and affective mentalizing. The 
RFS provides a single and global score.  
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Several differences can be highlighted concerning mentalization and metacognition. First, 
unlike mentalization, metacognition does not assume that the activation of the attachment system 
is the only source of disrupted abilities (Dimaggio, Semerari, Carcione et al., 2007). 
Furthermore, metacognition, when operationalized with the Metacognition Assessment Scale-
Revised (MAS-R; Carcione et al., 2010), evaluates separately different processes that can be 
disturbed. For example, the MAS-R has a specific subscale dedicated to the ability to use 
mentalistic information for purposeful problem solving, which allows to disentangle its unique 
role in psychopathology and psychotherapy (Carcione et al., 2011; Outcalt et al., 2016). 
Metacognition includes three broad functions. Understanding of one’s own Mind includes 
3 subfunctions: a) Monitoring, or the recognition and definition of cognitions and emotional 
states and the link between them and the behaviour. It is close to the concept of alexithymia, 
which includes the difficulties in identifying feelings and describing them to other people as well 
as a concrete and externally oriented style of thinking (Taylor, Bagby, & Parker, 1997); b) 
Differentiation is the ability to make a distinction between representations and reality, as 
thoughts are not objective descriptions of reality. A good level of differentiation would be “I 
thought that my entire life was a failure but then I realized it was only a thought and that good 
things happened to me too. It made me feel better about myself”; c) Integration relates to the 
construction of an integrated view of the self despite the variations in life events. 
The second function is the Understanding of Other’s Mind. It includes: a) Monitoring as 
the ability to identify what others are thinking and feeling and the connections between thoughts, 
affects and overt behaviour; b) Decentration refers to the ability to imagine that other people 
have their own perspective which is likely different from our own: “In his place, I would have 
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badly reacted to the waiter’s rudeness, thinking it was shameful to be treated like that. He stayed 
quite calm and polite, maybe thinking the waiter had had a bad day.”  
Mastery includes three levels of metacognitive reflection for the purpose of soothing 
suffering and solving interpersonal difficulties. The first level concerns strategies implying a 
limited use of information on mental states in order to solve problems, such as reducing 
emotional arousal by acting directly on the body (e.g. physical exercise). Dysfunctional 
strategies at this level include the use of drugs or self-harm. Second level strategies include the 
ability to purposefully alter one’s behaviour, for example inhibiting one’s action tendency, and 
re-focusing attention (e.g. deciding to stop worrying). Finally, the third level demands a greater 
metacognitive effort, such as taking a critical distance from thoughts or beliefs underpinning a 
problem, as well as using knowledge about the mental states of others to face interpersonal 
struggles. 
Metacognition in Borderline Personality Disorder 
 Poor metacognition has been suggested to be an aspect of core pathology of personality 
disorders (Semerari et al., 2007; 2014; 2015). Concerning BPD, it has been argued that 
metacognition is overall low, and in particular that patients struggle with distancing themselves 
from their own firmly held beliefs and with forming an integrated representation of self and 
others (Bateman & Fonagy, 2004; Livesley, 2003).  
Regarding the knowledge and understanding of one’s own state of mind in BPD, many 
studies have focused on poor emotional awareness, also labelled alexithymia (Taylor et al., 
1997). Poor affect awareness seems to be present in BPD (Levine, Marziali, & Hood, 1997; 
McMain et al., 2013; Joyce et al., 2013; New et al., 2012), though other studies have not found 
such a link (Nicolò et al., 2011). When analysing metacognition in patients’ discourse in both 
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psychotherapy sessions and semi-structured interviews, Semerari and colleagues (2005; 2014; 
2015) did not find poor awareness of one’s own affects and thoughts.  
Concerning the understanding of others’ state of mind, recent results suggest that patients 
presenting with BPD have difficulties in forming complex ideas about others and in seeing the 
world from the perspective of the others. These difficulties are made obvious when laboratory 
tasks are complex enough, mirror real-life conditions, or elicit distress (Brüne, Walden, Edel, & 
Dimaggio, 2016; New et al., 2012; Petersen, Brakoulias, & Langdon, 2016; Preissler et al., 2010) 
or when analysing patients’ discourse in semi-structured interviews (Dimaggio et al., 2009; 
Dinger et al., 2014; Outcalt et al., 2016; Semerari et al., 2005; 2014; 2015). 
The ability to regulate emotions is considered as a key problem in BPD and emotional 
dysregulation stems in part from poor emotional awareness (Linehan, 1993). BPD patients often 
use dysfunctional, nonmentalistic strategies (Bateman & Fonagy, 2004) in order to regulate 
unpleasant emotional states and psychological suffering, such as self-injury or substance abuse 
(Linehan, 1993; Scott, Stepp, & Pilkonis, 2014). This can be described as poor metacognitive 
mastery and can be demonstrated by low levels on the Mastery subscale of the MAS-R (Semerari 
et al., 2007). Mastery has been found impaired in BPD patients (Carcione et al., 2011; Outcalt et 
al., 2015). 
 BPD has been linked with difficulties in different areas of metacognition. Results are still 
inconsistent regarding the specific mentalistic impairments in BPD patients and further studies 
are needed to get a better understanding of them. In the light of the possible role of 
metacognition in BPD pathology, researchers focused on its evolution through psychotherapy 
and its impact on therapy outcome. 
Can metacognition change through psychotherapy? 
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Most psychotherapies for BPD are designed to improve patients’ mentalistic capacities 
(Bateman & Fonagy, 2004; Dimaggio, Montano, Popolo, & Salvatore, 2015) or to work in order 
to promote awareness of one’s own psychological functioning which likely foster abilities to 
reflect on mental states, such as the Good Psychiatric Management (GPM; Gunderson & Links, 
2014) adopted in the present study. In their 1-year RCT, Levy et al. (2006) compared the change 
in the RFS in patients in intensive psychotherapeutic treatments. The patients allocated to 
Transference-Focused Therapy (Kernberg, 1993) showed a significant increase in mentalizing 
while this improvement was not found in patients under Dialectical Behaviour Therapy 
(Linehan, 1993). Fischer-Kern and colleagues (2015) replicated the findings and found a unique 
improvement in the RFS in the sample treated with Transference-Focused Therapy compared to 
the control group treated by experienced community therapists. Nevertheless, it should be noted 
that other studies did not demonstrate such a linear change in RFS, notably in a hospitalization-
based psychodynamic treatment for PDs (Vermote et al., 2010; 2011). 
Studies using the MAS showed a trend in terms of improvement in metacognition 
through Cognitive-Behavioural Therapy and Metacognitive Interpersonal Therapy (Dimaggio et 
al., 2007) in case studies of various PDs (Dimaggio et al., 2009; Dimaggio, Procacci, et al., 2007; 
Semerari et al., 2003).  
Is metacognition a predictor of outcome? 
The idea that poor metacognition in BPD at therapy onset predicts outcome has yielded 
mixed findings. Alexithymia, measured with the Toronto Alexithymia Scale (TAS-20; Bagby, 
Parker, & Taylor, 1994), has been pointed out as an outcome predictor (Ogrodniczuk, Piper, & 
Joyce, 2011) but Joyce and colleagues (2013) did not replicate this finding, which might have 
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been due to clinicians’ increased capacities to deal early on with patients’ difficulties in 
describing their emotions, which could have reduced the toxic effect of alexithymia. 
Gullestad et al. (2013) found a moderator effect of RFS: patients with low RFS 
underwent a greater improvement in psychosocial functioning in an outpatient treatment. No 
difference was found between two treatment conditions for patients with medium or high levels 
of RF. Nevertheless, the study did not find a significant predictor effect of RFS on outcome. A 
longer 6-year follow-up of the same sample (Antonsen et al., 2016) found that patients with 
lower baseline RF had better outcomes in outpatient individual therapy as compared to patients 
with higher RF who achieved better outcomes in a group therapy based step-down treatment 
program.  
 Overall, metacognition is impaired in BPD and results are inconsistent in terms of 
metacognitive improvement during successful therapy. Metacognition, or related constructs as 
alexithymia and mentalizing, could be predictors of symptom change, but here again results are 
mixed. In light of inconsistencies from previous studies and given the lack of studies where 
metacognition as operationalized here was measured, to date we have no findings speaking for 
whether metacognition improves during psychotherapy for BPD and predicts outcome. 
Moreover, no study has yet examined the link between metacognition and symptom change in 
BPD patients in a short-term treatment. 
The present study 
 This preliminary pilot study is the first application of the MAS-R to a BPD sample and a 
first step in the exploration of the links between metacognition and symptom change in this 
population. An underlying goal is also to test the feasibility of this research design for a larger 
study, as MAS-R scorings require intensive training and time to be done in a methodical way. 
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This is the reason why we used a small convenience sample treated with a short version of the 
GPM (Gunderson & Links, 2014) from a previously published study (Kramer et al., 2014). 
Before attending to the hypothesised link between metacognition and symptom change, two 
preliminary research questions are explored: 
1. What is the level of metacognition before treatment? Though normative data for MAS-R do 
not yet exist, we expect low range scores of metacognition (e.g. < 2.5), which correspond to 
less than adaptive levels of metacognitive abilities.  
2. Does metacognition improve through short-term treatment? At this level, this hypothesis is 
exploratory. It may well be that either metacognition does not improve after ten sessions 
because it is not a treatment target in the approach adopted, or that it increases as GPM 
focuses among other elements on interpersonal functioning and its ties to the clinical 
symptoms. 
3. Finally, is there an association between the level of metacognition at intake and symptom 
change presented by BPD patients between the first and penultimate sessions of treatment? 
As the main hypothesis, we predict a positive link between metacognitive capacities at intake 
and symptom change during treatment. 
Method 
Participants 
A total of N = 10 patients were selected from a previously published study (Kramer et al., 
2014). In the latter, a total of 74 BPD patients were included and assigned either to a short-
version of the GPM treatment or to the same treatment where the Motive-Oriented Therapeutic 
Relationship (MOTR; Caspar, 2007), a form of therapeutic relationship based on an 
individualized case formulation, was added. Patients of the present study were randomly selected 
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from the GPM arm of the Kramer et al. (2014) study. We used the control sample and the basic 
treatment to test in a more rigorous manner our hypothesis of a link between metacognition and 
symptom change in the context of a minimum treatment intervention. A random selection was 
made, and comparison between our sample and the larger sample of Kramer et al. (2014) was 
tested with a naked eye assessment. Criteria were similar concerning the age, gender, fulfilled 
BPD criteria, employment and marital status. However, our sample reported more symptoms on 
the OQ-45 at intake (mean = 108.50, SD = 23.43) compared to the larger sample (mean = 95.00, 
SD = 27.00). Moreover, a higher rate of patients in the larger sample were using medication 
(60%) compared to our sample (20%). 
Our participants were 9 women and 1 man, all French-speaking, with a mean age of 33 
years (SD = 4; median = 32.50, IQR = 24). 7 patients were single, and 3 were married. 7 were 
unemployed and 3 were part-time working. Only 2 individuals had medication. Table 1 provides 
an overview of the main data and scores obtained by our patients at intake and at the end of the 
treatment. 
All patients were recruited from an outpatient university psychiatry clinic and provided 
written consent. Inclusion criteria were the following: being between 18 and 65 years old and 
having a SCID-II (First & Gibbon, 2004) confirmed diagnosis of BPD. Patients had on average 7 
(SD = 0.4; median = 7, IQR = 2.25) fulfilled BPD criteria on the SCID-II. Exclusion criteria 
were: existence of a psychotic disorder, mental retardation and substance abuse in the 
foreground. Comorbid psychiatric disorders are shown in Table 1. 
Therapists 
Five therapists were in charge of the treatment of the 10 patients included in our study: 1 
therapist treated 1 patient, 3 therapists treated 2 patients and 1 therapist treated 3 patients. All 
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therapists were working at the outpatient clinic where the patients were recruited for the study. 
They were psychiatrists and psychologists with at least 1 year of psychiatry residency and a basic 
psychodynamic background. Therapists were trained at the onset and during the study in the 
empirically validated GPM and the treatments were supervised twice during the whole process. 
Supervisors had training in psychodynamic therapy and had received a specific training in 
psychiatric management of BPD patients conforming to the GPM model (Gunderson & Links, 
2014). 
Treatment 
The patients received a 10-session treatment which is a short version of the GPM 
treatment for BPD patients. The elaborated treatment has the following goals: to establish 
psychiatric diagnoses, comorbidities, and psychiatric anamnesis; to define the main topics and 
the treatment target; to identify short-term objectives; to name and deal with difficulties 
interfering with the treatment; and finally to formulate the relational interpretations of core 
conflictual themes (Kramer et al., 2014). The GPM model was integrated as a useful first-line 
treatment and as a preparation for a long-term psychotherapy (Kolly et al., 2016). 
Treatment fidelity was assessed using the General Psychiatric Management Adherence 
Scale (Kolla et al., 2009) and showed high treatment integrity (Kramer et al., 2014). Each 
assessment, as well as the adherence observer ratings, was generally made by 1 research assistant 
with the help of 3 other research assistants when needed. 
Instruments 
Comorbid psychiatric disorders  
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Comorbid psychiatric disorders on axis I and II were assessed by two structured 
interviews: the Mini International Neuropsychiatric Interview (Lecrubier et al., 1997) and the 
SCID-II (First & Gibbon, 2004). 
The Outcome Questionnaire-45.2 (OQ-45; Lambert, Morton, Hatfield, et al., 2004) aims 
to assess mental health functioning and its evolution during psychotherapy. The items are 
assessed on a 4-point Likert scale, ranging from 1 (never) to 4 (always). A global score is then 
calculated. The clinical cut-off for the global score is 63. It has been translated and validated in 
French (Emond et al., unpubl. data). The scale was given after the first and penultimate sessions. 
It was filled in between sessions, at home by the patients. Cronbach’s alpha for the total score 
was α = 0.94.  
The Metacognition Assessment Scale-Revised (MAS-R; Carcione et al., 2010) detects 
metacognitive change in individual’s narratives and was originally developed for psychotherapy 
transcripts and specialized interviews. It provides a global score of metacognition and a score for 
three subscales with several subfunctions: 
1) Understanding of one’s own Mind (UM subscale) measures the ability of a person to think 
about its own mental states. It includes Monitoring, Differentiation and Integration 
subfunctions previously described (see Introduction). 
2) Understanding of Other’s Mind (UOM subscale) assesses the ability to think about the 
mental states of others. It includes the Monitoring of others’ mental states and the 
Decentration subfunctions. 
3) Mastery (M subscale) is the representation of mental states involving suffering or 
psychological conflicts and the adoption of an active attitude to use mentalistic information 
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to soothe suffering and solve conflicts. It includes three different levels, from a more 
behavioural to a more metacognitive level.  
 For each subfunction, ratings are made on a 5-point scale from 1 = “scarce” (sporadic, 
poorly articulated, not spontaneous, probing does not generate improvement) to 5 = 
“sophisticated” (sustained talk about mental states, descriptions are rich, talk of mental states is 
spontaneous or there is an autonomous elaboration of a question/suggestion). In case a 
subfunction does not occur in the interview, the MAS-R gives the possibility to score it as “Not 
Engaged”. 
 Lysaker et al. (2007) found significant correlations among the three subscales of the 
MAS-A, the previous version of the MAS-R. Because of our small sample size, we did not 
perform such correlational analyses here. They will be carried out on a larger sample in a future 
study. 
MAS-R assessment and rating 
For each patient, the first and penultimate sessions were tape-recorded and transcribed 
(Mergenthaler & Stigler, 1997). After dividing the transcripts into scoring units, two independent 
raters, the first and the second authors, scored them with the MAS-R. Both were blind to any 
details regarding the sample and the sessions. The second author was one of the creators of the 
MAS-R and the first author was trained by the latter until good reliability was achieved. A 
consensus rating was used for the data. On the 20 sessions coded, two were used for training 
purposes, so inter-reliability in assessing the metacognitive subfunctions was not calculated for 
them. Inter-rater reliability was therefore calculated for 90% of the transcripts (N = 18) with 
Intra-Class Coefficients (Shrout & Fleiss, 1979). It was good to excellent, with a mean ICC(2,1) 
= .85 (SD = .01, range = .70 - .91).  
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Statistical analyses 
Kolmogorov-Smirnov and Levene’s tests were used to assess the normality and 
homogeneity of variance of the data and help to select the proper statistical analyses. An 
evaluation of the total score and subfunction scores of metacognition were provided using item-
mean scores. We then used the Wilcoxon signed-rank test to compare differences between scores 
in MAS-R at intake and after ten sessions. Finally, Spearman correlations were used to determine 
the link between metacognition and symptoms as measured through the OQ-45. For this, we 
subtracted the OQ-45 score after ten sessions from the score obtained at onset in order to get the 
delta value. Given the exploratory nature of the study, no Bonferroni correction for the number 
of tests was made.  
Results 
Preliminary analyses 
Metacognition scores. Table 2 presents the scores obtained by participants at each 
subscale at intake and at the end of the treatment. Our sample showed a MAS-R mean score of 
1.77 (SD = 0.36; median = 1.58, IQR = 1.48) at onset, and a MAS-R mean score of 1.93 (SD = 
0.48; median = 1.86, IQR = 0.83). 
Metacognitive change in a 10-session treatment. Regarding the evolution of MAS-R 
scores between the first and the penultimate session, even if an improvement is observed, the 
differences were not significant, except for the first-level Mastery strategies (z = 1.96, p = .05; 
Table 2). 
Links between metacognition and symptoms. For our main hypothesis, we first tested 
if patients improved in terms of symptoms. They showed a mean symptom level of 108.5 (SD = 
7.4), median = 113.50 (IQR = 4, range = 71-144) on the total OQ-45 at intake and a mean of 77.4 
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(SD = 10.2), median = 77 (IQR = 42, range = 19-130) after 9 sessions, this difference being 
significant (z = -2.4, p<.05; ES = 3.49). 
Then, Spearman correlations revealed a link between the metacognitive level at intake 
and symptom change (Table 3). More precisely, the total MAS-R score at the beginning of 
treatment tended to be linked with symptom change during treatment measured by the OQ-45 
delta (rs = -.52, p = .06). Focusing on the three subscales of MAS-R, the UM and M subscales 
did not show links with the change on the OQ-45. In contrast, we found a relationship between 
the UOM subscale and symptom reduction (rs = -.56, p < .05).  
Clinical examples 
To illustrate the metacognitive impairments our patients suffer from, clinical examples 
are presented below. They are verbatims from the session transcripts. Patient 3 is a 35-year-old 
female who had a low score in the UM scale at onset (mean = 1.69). She’s talking about her 
mood swings: 
Therapist: So, you always relapse. Can you describe to me how this happens? 
Patient: It’s feels like a depression, but it happens suddenly, it is not progressive. Suddenly I feel 
bad, I don’t have anymore desires, I want to die, to call for help, to do drugs... 
T: That’s it. 
P: But I don’t feel the emotional changes coming up, I feel bad only 2-3 days or 2-3 weeks 
before. 
T: And at that moment, what is going on? 
P: It depends on the degree of sadness or on external events in fact. Sometimes I can call for help 
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and say “now I need medicine because something’s wrong”, or it becomes bigger and bigger 
and I say to myself “anyway there is no point to call for help, that won’t fix the problem, my 
partner is not able to understand my suffering” and I hurt myself.  
In this example, she describes a lack of differentiation. She does not take a critical 
distance from her own beliefs and thoughts (“anyway there is no point to call for help, that won’t 
fix the problem, my partner is not able to understand my suffering”) are considered as being 
reality. Moreover, we can observe a low level of Mastery here (use of self-harm). A better 
differentiation ability is illustrated by Patient 10 (mean UM at onset = 3.17), a 55-year-old man 
talking about a situation that triggered disappointment: 
T: How did that make you feel? 
P: Mmmh… disappointment, I felt disappointed and irritated. And even though I consider myself 
to be a flexible person… perhaps I’m not. Perhaps I consider myself to be flexible and in reality 
I’m not.   
In his reflective process, he can take a critical distance from his thoughts, to the point of 
considering that they may not necessarily mirror reality. 
Discussion 
This preliminary pilot study aimed to investigate several questions regarding 
metacognition in therapy and its connection with symptom change within a sample of patients 
presenting with BPD.  
We expected that metacognitive abilities were in low range, and the scores obtained by 
patients seem to confirm this. In relation to previous research, we found that the present sample 
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had equal levels of metacognition compared to samples of psychotic patients (MacBeth et al., 
2014; Mitchell et al., 2012). This is in line with conceptual, clinical and research work showing 
that metacognitive abilities in BPD patients can be severely impaired (Bateman & Fonagy, 2004; 
Kernberg, 1993; Semerari et al., 2005). As the psychometric properties of this scale are not 
formally established yet, our study makes a first contribution to how severe the metacognitive 
deficits in BPD could be. It also gives an idea about their nature, with impairments in every 
dimension and very prominent problems in the use of mentalistic information in order to cope 
with life challenges (mastery). 
Second, we also aimed to explore the evolution of metacognition through a 10-session 
treatment. Even if a trend towards a positive evolution was shown in the majority of 
metacognitive dimensions, the difference between the first and penultimate sessions was only 
significant for the first-level Mastery strategies. This result has to be taken with caution because 
of the sample size and the multiple testing carried out. Moreover, even if the difference reached 
the significance threshold, we are not able to conclude that a clinical change occurred, as the 
MAS-R score at the end is still under a moderate level of metacognition. A significant clinical 
change may occur with a long-term treatment or a treatment focused on metacognition. 
However, as a basis for hypotheses for future studies, several comments can be made: strategies 
which use a limited amount of mentalistic knowledge in order to solve problems, e.g. 
understanding one is distressed and undertaking physical exercise in order to calm oneself down, 
require a low reflective ability. This could partially explain the quick improvement of this 
subfunction compared to the others for which long-term treatment is necessary (Bateman & 
Fonagy, 2009; Carcione et al., 2011; Levy et al., 2006). It is likely that either because of their 
growing sense of trust in the therapist or because they were offered simple instructions on how to 
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cope with suffering, patients learned to identify distress and tolerate it. More complex abilities 
such as calming oneself down thanks to a more comprehensive view of oneself and others did 
not develop. This is to be expected because treatment was very short. Research is needed to see 
whether the GPM is able to promote metacognition when applied for longer periods and, more 
generally, whether different treatments are able or fail to promote metacognition.  
Finally, we assumed a link between early levels of metacognitive skills and symptom 
change. The global level of metacognition at intake seems to be linked with symptom decrease 
during treatment, even if this trend did not reach statistical significance. A link was found for 
intake sessions showing a greater ability to grasp the others’ states of mind and reflect on them. 
Sessions characterized by higher level in this domain at the beginning of treatment seem to be 
connected with greater outcome. Again, as this exploratory study included a small sample size, 
there is an urgent need for replication in a larger sample and results are to be considered 
preliminary at best. Nevertheless, a possible explanation for this result, if replicated, is that with 
reduced capacity to understand the mental states of other people at the beginning of the therapy, 
patients have more difficulty understanding the therapist’s perspective and the use of therapy. 
Thus, they will have problems in adopting new perspectives coming from the therapeutic 
exchange and using those to deal effectively with social challenges in the short term. It is also 
possible that with reduced understanding of the state of mind of others, BPD patients feel more 
alone when suffering and deprived of social support. Nevertheless, it is possible that these 
metacognitive abilities were moderated by the therapist’s techniques. 
The indication of a possible relation between metacognition and symptoms underlines the 
necessity to take into consideration the abilities of patients to recognize and understand mental 
states of other individuals, including the therapist, as a common principle of change in therapy 
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for BPD. A hypothesis could be that early in treatment, the level of metacognition reveals 
something about the potential evolution of the patient’s symptoms throughout treatment. In this 
case, it would be possible for the clinician to assess and detect early difficulties in metacognition 
and then deliver the appropriate intervention according to the patient’s capacities and with an 
attempt at improving them progressively as prescribed in Mentalization-Based Treatment 
(Bateman & Fonagy, 2004) or in Metacognitive Interpersonal Therapy (Dimaggio, Montano, 
Popolo, & Salvatore, 2015). Indeed, both symptoms and interpersonal functioning have to be 
prime targets in therapeutic treatments for PD patients (Bateman & Fonagy, 2004; Linehan, 
1993; Livesley, 2003; Livesley et al., 2016).  
This preliminary pilot study also shows the importance of taking into account separate 
dimensions of metacognition. Indeed, if we only had considered the total MAS-R score, precious 
information would have been lost, such as the role and predictive value of the ability to reflect 
upon other’s states of mind on symptom change. These results are in line with a 
conceptualisation of metacognition as a complex and multi-factorial concept (Semerari et al., 
2003, 2005, 2007). 
A number of limitations need to be highlighted in this preliminary pilot study. First of all, 
it involved a small convenience sample which makes it difficult to generalize and limits the 
statistical power of the results, making the results tentative at best. As an example, we can cite 
the high effect sizes found (Table 2), which are probably not robust in such a small sample. 
Moreover, our sample had a very high female prevalence (9/10), which also contributes to the 
low generalizability of the results. Furthermore, the sample showed a metacognition level 
comparable to the one obtained by psychotic patients. As this present study is the first to use the 
MAS-R in a BPD sample, no data comparison yet exists. It is therefore difficult to estimate if our 
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sample is representative of BPD patients in terms of metacognition levels. For all these reasons, 
future studies should include a control/comparison group in order to make firm conclusions 
about the specificity of metacognitive change. It is still conceivable that different therapeutic or 
relational techniques can have an impact on metacognitive processes (Semerari et al., 2003). 
Kramer, Caspar, and Drapeau (2013), for example, showed the impact of the MOTR (Caspar, 
2007) on decreasing cognitive biases. It is possible that patients treated in the other arm of the 
trial (Kramer et al., 2014) from which our sample is taken, where the MOTR was used, could 
have showed a different pattern of prediction of metacognition over symptoms and of 
metacognitive change. Another limitation is that the transcripts come from therapy sessions and 
patients’ metacognitive abilities do not only depend on the patients themselves, but also strongly 
on the therapist’s ability to work consistently with the patient’s metacognitive level. Therefore, 
there is the need to replicate the finding with patients treated by different therapists coming from 
different therapeutic approaches, in order to explore whether addressing metacognitive problems 
can be considered part of an integrated treatment for BPD. A further limit is that our main 
outcome, the symptom level, was self-reported by patients; therefore, the need for observer-rated 
measures of change remains. It was also administrated in a non-standard manner (after and not 
immediately prior to session). Finally, short-term treatment results were analyzed and do not 
inform us more about long-term effects, especially considering that metacognitive skills require 
time to grow and exert their beneficial effects on symptoms and social functioning (Carcione et 
al., 2011; Dimaggio et al., 2009; Levy et al., 2006; Semerari et al., 2005). 
Irrespectively of their therapeutic orientation, clinicians can focus on problems in the 
different metacognitive domains and adjust their response to the patients’ current abilities to 
make sense of mental states, taking into account the heterogeneity in BPD patients (Bateman & 
METACOGNITION AND SYMPTOM CHANGE IN BPD 
 23 
  
Fonagy, 2004; Leiman & Stiles, 2001; Levy & Scala, 2015; Ribeiro et al., 2013; Semerari et al., 
2007). For example, a combination of first-line interventions aimed at promoting basic mastery 
strategies, which would produce good outcomes, can be coupled with interventions aimed at 
improving basic self-reflective skills, such as awareness of one’s own mental processes. In later 
stages, the focus would move on to promoting the understanding and the use of more complex 
mental states. 
In summary, our preliminary results are in line with previous studies showing strong 
impairments in mentalistic abilities in psychotherapy with patients presenting with BPD. The use 
of the MAS-R could allow to draw a more precise map of the impairments in BPD metacognitive 
abilities as well as to quantify the impact of these on symptom change during short-term 
treatments. This preliminary study highlighted the need for further research: first, confirming the 
role of patients’ metacognitive abilities in the early sessions of treatment on symptom evolution; 
second, exploring the impact of the therapist and the therapeutic relationship on metacognition. 
Such studies are currently in progress.  
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Table 1 
Characteristics of the ten patients 
 
* 1 = depression, 2 = dysthymia, 3 = anorexia, 4 = bulimia, 5 = panic disorder, 6 = alcohol abuse, 7 = intelligence 
limitation 
 
 
 
 
 
Table 2 
Subjects Age Gender GAF at 
intake 
Comorbidities 
on axis I * 
MAS-R total scores  OQ-45 total scores 
     Intake Penultimate 
session 
Intake Penultimate 
session 
1 30 Female 50 1 1.54 1.58 144 130 
2 19 Female 55 3 1.52 1.76 71 84 
3 35 Female 60 1 1.62 2.00 77 45 
4 22 Female 60 1, 6 1.92 1.96 125 61 
5 26 Female 65 2 1.84 2.54 131 118 
6 20 Female 60 1, 3 1.52 2.67 116 71 
7 44 Female 50 1, 4 2.52 1.60 112 77 
8 48 Female 60 1, 5 1.56 1.74 89 77 
9 37 Female 60 7 2.24 2.38 115 19 
10 55 Male 60 2, 6 1.46 1.12 105 92 
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Means of MAS-R scores obtained by patients at intake and after ten sessions 
MAS-R scales and subscales 
Intake 
 Mean (SD) 
Median (IQR) 
Penultimate 
session 
Mean (SD) 
Median (IQR) 
                    
z 
                   
p Effect 
size 
MAS-R total 1.77 (.36) 
1.58 (.48) 
1.93 (.48) 
1.86 (.83) 
1.27 .20 -.37 
 
Understanding of one’s own Mind 
(UM) 
  
 
Monitoring 
 
 
Differentiation 
 
 
Integration 
 
2.24 (.16) 
2.05 (.82) 
 
2.80 (.65) 
2.72 (.11) 
 
1.62 (.55) 
1.41 (.83) 
 
1.42 (.51) 
1.20 (.81) 
 
2.37 (.18) 
2.41 (.85) 
 
2.75 (.70) 
2.88 (.86) 
 
1.88 (.55) 
1.66 (.71) 
 
1.88 (.69) 
1.66 (1.26) 
 
.66 
 
 
.66 
 
 
1.13 
 
 
1.25 
 
.51 
 
 
.51 
 
 
.26 
 
 
.21 
 
-.76 
 
 
.07 
 
 
-.47 
 
 
-.75 
 
Understanding of Other’s Mind 
(UOM) 
 
 
Monitoring 
 
 
Decentration 
 
1.49 (.13) 
1.47 (.83) 
 
1.58 (.45) 
1.66 (.86) 
 
1.31 (.38) 
1.17 (.63) 
 
1.56 (.14) 
1.47 (.87) 
 
1.63 (.46) 
1.60 (.82) 
 
1.37 (.48) 
1 (1) 
 
.56 
 
 
.56 
 
 
.41 
 
.58 
 
 
.58 
 
 
.68 
 
-.52 
 
 
-.11 
 
 
-.14 
 
Mastery (M) 
 
 
 Basic requirements 
 
 
 1st level strategies 
 
 
1.58 (.11) 
1.58 (.64) 
 
1.80 (.63) 
1.83 (1.17) 
 
1.41 (.30) 
1.45 (.39) 
 
1.88 (.17) 
1.89 (.64) 
 
2.20 (.59) 
2.33 (1) 
 
1.94 (.62) 
2 (1.21) 
 
1.38 
 
 
1.50 
 
 
1.96 
 
 
.17 
 
 
.14 
 
 
.05 
 
 
-2.06 
 
 
-.66 
 
 
-1.06 
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2nd level strategies 
 
 
3rd level strategies 
 
1.75 (.49) 
1.75 (.83) 
 
1.69 (.21) 
1.67 (.67) 
 
1.76 (.60) 
1.5 (.75) 
 
1.86 (.62) 
2 (.93) 
 
-.95 
 
 
.74 
 
.34 
 
 
.46 
 
-.02 
 
 
-.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
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Correlations between metacognition at intake and symptom change (delta OQ-45) 
 rs  p  
MAS-R Total -.52 .06 
Understanding of one’s own Mind (UM) -.40 .12 
Understanding of Other’s Mind (UOM) -.56 .04 
Mastery (M) -.43 .10 
All correlations are Spearman’s rho. 
 
 
 
 
 
 
 
 
